nfluenza epidemics occur in most parts of the world and typically arise every 2 to 3 years, causing approximately 20,000 deaths above the yearly mortality baseline (1) . The incidence of recurring epidemics is primarily attributed to the high frequency of mutational changes in the hemagglutinin (HA) and neuraminidase (NA) major surface glycoproteins. The hemagglutinin protein, responsible for viral uptake into host epithelial cells, is also the antigen targeted by antibodies. The HA1 subunit of the H1N1 hemagglutinin protein consists of the globular head and contains five major antibody binding sites: Sa, Sb, Ca 1 , Ca 2 , and Cb (2) (3) (4) (5) . Mutational changes (antigenic drift) at these four sites are thought to be driven by selective antibody pressure, which can produce novel strains capable of evading the immunologic response. Monitoring the antigenic drift of viruses in global populations is essential for optimal selection of component strains for the annually updated trivalent influenza vaccine.
Since 1976, the United States Air Force (USAF) has contributed to influenza surveillance through a collaborative partnership with the Centers for Disease Control and Prevention (CDC) and World Heath Organization (WHO) (6) (7) . In 1997, the USAF expanded surveillance to include US Navy and Army installations and became the Department of Defense Global Emerging Infections System (DOD-GEIS) (6) . The DOD-GEIS influenza surveillance network receives samples from training bases, ports of entry, and many military sentinel sites in the United States, Pacific Rim, and Europe, and throughout Central and South America.
Since 1995, the predominant Influenza A viruses, type H1N1 isolated in North and South America were closely related to A/Bayern/7/95, while viruses belonging to another genetic and antigenic lineage of H1N1 viruses, A/Beijing/262/ 95, have remained geographically restricted to Asia (8) (9) (10) . During spring 1999, Beijing/262/95-like variants, containing a characteristic deletion mutation at amino acid 134 of the HA gene, were isolated from 13 persons at a DOD-GEIS influenza surveillance site in Lima, Peru. These antigenically distinct H1N1 viruses were closely related to A/New Caledonia/20/99, a recently characterized variant from the Beijing/262/95 lineage. Before these Peru isolates, no circulation of amino acid-134 deletion mutants in the Americas was documented.
Materials and Methods

Sources of Specimens
Influenza throat swab specimens were collected in accordance with the case criteria outlined in Canas et al. (6) . The criteria included patients with a fever >37.8°C accompanied by cough or sore throat. Throat swabs were taken within 72 hours of the onset of symptoms, placed in viral transport media (MicroTest, M4) (VTM), and delivered via commercial carrier to the clinical laboratory at the Epidemiological Surveillance Division, Brooks Air Force Base. The two influenza isolates used in this study were randomly selected from 13 positive patient samples isolated from February to April 1999 from a Department of Defense sentinel site in Lima, Peru.
*Brooks Air Force Base, San Antonio, Texas, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA
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Viral Detection
All influenza viruses examined in this study were passaged one time through Primary Rhesus Monkey Kidney (PMK) tissue culture (Viro-Med, Minneapolis, MN; BioWhittaker, Walkersville, MD). A total of 500 ml of VTM was injected onto a shell vial containing a coverslip with PMK tissue culture. Cultures were tested for viral infection using the centrifugation-enhanced shell-vial technique that includes a cell monolayer grown on a coverslip contained in a shell vial. Specimens are inoculated onto the cell monolayer, subjected to a low speed centrifugation for 60 minutes, incubated at 35°C for 48 hours to 72 hours and then screened with monoclonal antibodies (Chemicon, Inc., Temecula, CA) to detect the presence of Influenza A or B viruses. Aliquots of all specimens used in this study for the purposes of genetic analysis were stored at -80°C until use.
Antigenic and Genetic Typing
For antigenic analysis, aliquots of each isolate were sent to CDC for characterization in hemagglutiniation inhibition (HI) tests with postinfection ferret antisera as previously described (11) .
For genetic typing, approximately 1 mL of VTM was used to infect PMK tissue culture (Viro-Med, Minneapolis, MN; BioWhittaker, Walkersville, MD) and incubated at 37°C for 3 to 5 days. RNA was extracted from a 300 µl aliquot of tissue culture fluid using the High Pure Viral RNA Kit (BoehringerMannheim, Indianapolis, IN). Influenza RNA was amplified into double stranded DNA by reverse transcription and polymerase chain reaction (RT-PCR) using the Titan One Step RT-PCR Kit (Boehringer-Mannheim). An 1,187 bp cDNA fragment consisting of the HA1 coding region of influenza A hemagglutinin was amplified using forward primer F6-(5'-AAGCAGGGGAAAATAAAA-3', mRNA) and reverse primer R1193-(5'-GTAATCCCGTTAATGGCA-3', vRNA sense). The RT-PCR reaction was performed by using a Perkin Elmer 2400 thermocycler (Forest City, CA). The PCR product was purified using the QIAquick spin column purification (Qiagen, Valencia, CA). Purified HA1 amplicon was cycle sequenced by using the Big Dye Terminator Cycle Sequencing Kit (PE Biosystems) run on a 377-XL automated DNA sequencer according to manufacturer recommendations (PE Biosystems). Four internal oligonucleotide sequencing primers (Table 1) were used to sequence the entire HA1 amplicon in both the forward and reverse directions. Multiple sequence alignments, protein translation, and phylogenetic analysis were performed by using the software package Lasergene (version 3.18) (DNAS-TAR, Madison, WI). The nucleotide and amino acid sequences for A/Peru/1621/99 and A/Peru/1798/99 are available from Genbank under the accession numbers AF268313 and AF268312, respectively. Additional nucleotide and amino acid sequences characterized by Brooks Air Force Base and depicted in phylogenetic analysis are available from Genbank under the accession numbers AY029287-AY029292.
Results
Antigenic Analysis
Antigenic characterization by HI, using postinfection ferret antisera, was performed with reference antigens representing two globally cocirculating Influenza A virus, type H1N1 antigenic/genetic lineages (A/Beijing/262/95, which includes the variant A/New Caledonia/20/99; and A/Bayern/07/95, which includes A/Johannesburg/82/96). Both Peru isolates were antigenically related to the A/Beijing/262/95 rather than to the A/ Bayern/07/95 lineage ( Table 2 ). Both Peru isolates were antigenically close to the new variant, A/New Caledonia/20/99, that recently evolved from the A/Beijing/262/95 virus. H1 titers of the Peru isolates were within a two-fold difference from the homologous titer demonstrated by A/New Caledonia/ 20/99 (160 vs. 320), while they were fourfold lower than the A/Beijing/262/95 homologous titer (160 vs. 640).
Genetic Analysis
The complete nucleotide and deduced amino acid sequences of the HA1 of the two Peru isolates were compared with those of the previous vaccine strain, A/Beijing/262/95, and the current vaccine strain, A/New Caledonia/20/99. Based on nucleotide alignments, A/Peru/1621/99 and A/Peru/1798/ 99 share identical HA1 sequences and are genetically closer (97.9%) to A/New Caledonia/20/99 (97.9%) than they are to Figure 1 
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Sequence comparisons further supported the results of the antigenic analysis. Eleven amino acid differences in the HA1 protein were observed between the Peru isolates and A/ Beijing/262/95, the vaccine strain for the 1998-99 and 1999-2000 influenza seasons. Four of these 11 substitutions were located in 3 antigenic sites and could potentially alter antibody-binding properties of the viruses. Wilson and Cox proposed that a drift variant of epidemiologic importance usually contains four or more amino acid substitutions located in two or more of the antigenic sites on the HA1 protein (14) . Substitutions at residues 218(A218T) and 225(G225D) were present in the Ca antigenic site located approximately halfway down the side of the HA1 globular head (3, 15) . Two other substitutions, 82(E82D) and 166(N166K), were observed within antigenic sites Cb and Sa, located at the base and tip of the HA1 globular head, respectively (3, 15) .
Genetic comparisons between Peru isolates and A/New Caledonia/20/99 show a difference of only eight amino acids (Figure 1 (20) .
Studies based on amino acid analyses of viruses from previous years to predict the evolution of future H1N1 epidemic strains would be advantageous as a surveillance tool and could contribute to the vaccine selection process. Using a retrospective approach, Bush et al. determined that specific codons in the HA1 domain of the hemagglutinin gene of human influenza subtype H3 are under positive selection to mutate (21) (22) . Certain amino acids in the HA1 of human H1N1 viruses mutate at positively selected codons, giving rise to new viral lineages. The characterization of these Peru variants emphasizes the need to be vigilant in examining sublineage amino acid changes that may be indicators for the emergence of future strains.
The effectiveness of an annually determined trivalent influenza vaccine depends on choosing component strains that offer optimal immunity from the numerous variants in global circulation. In addition, timing is critical because the vaccine strains are selected months before the onset of influenza season to ensure the production of adequate amounts of vaccine by drug manufacturers.
